A Study to Evaluate a Single Intravenous (IV) Dose Using a New Manufactured Clone and Single Ascending Doses of Subcutaneous (SC) Injections

Inclusion Criteria: * The subject weighs at least 50 kg, a maximum of 92.5 kg and has a body mass index (BMI) of 18.0 to 32.0 kg/m2, inclusive * The subject's 12-lead electrocardiogram (ECG) results are normal * The female subject must be at least two years postmenopausal OR surgically sterile and not pregnant or lactating * The male subject agrees to the use of male condoms until the end of study or 60 days post dose, whichever is longer Exclusion Criteria: * The subject has a history of any clinically significant cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, and/or other major disease or malignancy excluding adequately-treated non-melanoma skin cancer * The subject has a history of severe allergic or anaphylactic reactions * The subject is a female of childbearing potential * The subject has a history of consuming more than 14 units of alcoholic beverages per week or has a history of alcoholism or drug/chemical/substance abuse within the past 2 years (Note: one unit = 12 ounces of beer, 4 ounces of wine or 1 ounce of spirits) * The subject has a positive test for alcohol or drugs of abuse * The subject has/had a symptomatic, viral, bacterial (including upper respiratory infection), or fungal (non-cutaneous) infection within 1 week prior to clinic check-in * The subject has a past history of opportunistic infection * The subject has a supine mean systolic blood pressure \< 90 or \> 160 mmHg and a mean diastolic blood pressure \< 50 or \> 90 mmHg, or mean pulse rate higher than 100 beats per minute (bpm) * The subject is known positive for human immunodeficiency virus (HIV) antibody * The subject has a positive tuberculosis (TB) skin test, Quantiferon Gold test or T-SPOT® test * The subject has a positive test for hepatitis C antibody, or positive test for hepatitis B surface antigen (HBsAg), or positive hepatitis B core antibody * Subject's alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) values are greater than 1.5 times the upper limit of normal * Subject's laboratory test results are outside the normal limits and considered to be clinically significant * The subject received any vaccine within 60 days prior to study drug administration * The subject received any systemic immunosuppressant agent within 2 months prior to study drug administration * The subject has previously received any antibody or therapeutic biologic product prior to study drug administration * The subject received any systemic steroid within 2 months or steroid inhaler within 1 month prior to study drug administration * The subject has had treatment with prescription, non-prescription or complementary and alternative medicines (CAM) within 14 days prior to study drug administration with the exception of stable hormone replacement therapy (HRT) and/or intermittent acetaminophen (to a maximum of 2 g/day) * The subject has received an experimental agent within 30 days or five half-lives, whichever is longer, prior to study drug administration * The subject is participating in another clinical trial or has participated in another dose group of the current trial * The subject has had any significant blood loss, donated one unit (450 mL) of blood or more, or received a transfusion of any blood or blood products within 60 days or donated plasma within 7 days prior to clinic admission * The subject has any other condition which precludes the subject's participation in the trial * The subject has a history of heavy smoking or has used tobacco-containing products and nicotine or nicotine-containing products in the past six months